Eric Faulkner, Practice Leader, Consulting at Quintiles discusses the impact on HTA and budget holders of an increasing trend towards personalized medicines and orphan drugs.  He highlights considerations such as how to value medicines amidst increasing cost scrutiny and how we adapt to this environment in this area to ensure that these valuable products are made available to patients.